Treating diabetes with islet transplantation: Lessons from the past decade in Lille

Diabetes and Metabolism

Volumn 40, Issue 2, 2014, Pages 108-119

  Vantyghem, M C ^a   Defrance, F ^a   Quintin, D ^a   Leroy, C ^a   Raverdi, V ^a   Prevost G ^b   Caiazzo, R ^a   Kerr Conte, J ^a   Glowacki, F ^a   Hazzan, M ^a   Noel, C ^a   Pattou, F ^a   Balavoine, Diamenord A S ^c   Bresson, R ^d   Bourdelle Hego, M F ^e   Cazaubiel, M ^c   Cordonnier, M ^f   Delefosse, D ^g   Doreyi, F ^f   Fayard, A ^g   Fermon, C ^h   Fontaine, P ^a   Gillot, C ^d   Hayem S , ⁱ   Le Guillou, A C ^a   Karrouz, W ^a   Lemaire, C ^d   Lepeut, M ^h   Leroy, R ⁱ   Mycinski, B ^j   Parent, E ^c   Siame, C ⁱ   Sterkers, A ^a   Torres, F ^a   Verier Mine, O ^f   Verlet, E ^k   Desailloud, R ^l   Durrbach A ^m   Godin, M ^b   Lalau, J D ^l   Lukas Croisier, C ⁿ   Thervet, E ^o   Toupance, O ⁿ   Reznik, Y ^p   Westeel, P F ^l   more..

^a LILLE UNIVERSITY HOSPITAL   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c Tourcoing Hospital   (France)

^d Douai General Hospital   (France)

^e University Hospital Bethune   (France)

^f Department of Cardiology   (France)

^g Arras General Hospital   (France)

^h Bacteriology laboratory   (France)

ⁱ Clinic of La Louvière   (France)

^j Department of Neurology   (France)

^k Dunkerque General Hospital   (France)

^l AMIENS UNIVERSITY HOSPITAL   (France)

^m INSERM U1014   (France)

ⁿ REIMS UNIVERSITY HOSPITAL   (France)

^o INSERM   (France)

^p CHU CÔTE DE NACRE   (France)

more..

Author keywords

Beta score; Brittle diabetes; Diabetes cell therapy; Islet transplantation; Type 1 diabetes

Indexed keywords

C PEPTIDE; DACLIZUMAB; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; RAPAMYCIN; REPARIXIN; TACROLIMUS; C REACTIVE PROTEIN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT;

ALLOIMMUNITY; AUTOIMMUNITY; BLOOD GLUCOSE MONITORING; CLINICAL PROTOCOL; DIABETIC MICROANGIOPATHY; DISEASE COURSE; FEASIBILITY STUDY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; NEUROPATHY; PANCREAS ISLET TRANSPLANTATION; PHASE 2 CLINICAL TRIAL (TOPIC); PORTAL VEIN THROMBOSIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PAIN; POSTOPERATIVE VOMITING; QUALITY OF LIFE; REPRODUCIBILITY; RETINOPATHY; REVIEW; SYSTEMATIC REVIEW; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSE BLOOD LEVEL; IMMUNOLOGY; MALE; METABOLISM; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84899050881     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2013.10.003     Document Type: Review

References (61)

1. Pattou F., Vantyghem M.C., Noel C., Kerr-Conte J., Gmyr V., Martinache I., et al. Sequential intraportal islet allografts in immunosuppressed type I diabetic patients: preliminary results. Transplant Proc 2000, 32:391-392.
2. Vantyghem M.C., Fajardy I., Pigny P., Noel C., Kerr-Conte J., Gmyr V., et al. Kinetics of diabetes-associated autoantibodies after sequential intraportal islet allograft associated with kidney transplantation in type 1 diabetes. Diabetes Metab 2003, 29:595-601.
3. Shapiro A.M., Lakey J.R., Ryan E.A., Korbutt G.S., Toth E., Warnock G.L., et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000, 343:230-238.
4. Ryan E.A., Paty B.W., Senior P.A., Bigam D., Alfadhli E., Kneteman N.M., et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005, 54:2060-2069.
5. Shapiro A.M.J., Ricordi C., Hering B.J., Auchincloss H., Lindblad R., Robertson R.P., et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006, 355:1318-1330.
6. Vantyghem M.C., Kerr-Conte J., Arnalsteen L., Sergent G., Defrance F., Gmyr V., et al. Primary graft function, metabolic control, and graft survival after islet transplantation. Diabetes Care 2009, 32:1473-1478.
7. Tattersall R.B. Brittle diabetes revisited: the third Arnold Bloom memorial lecture. Diabet Med 1997, 14:99-110.
8. Zhou J., Li H., Ran X., Yang W., Li Q., Peng Y., et al. Reference values for continuous glucose monitoring in Chinese subjects. Diabetes Care 2009, 32:1188-1193.
9. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Fox L.A., Beck R.W., Xing D. Variation of interstitial glucose measurements assessed by continuous glucose monitors in healthy, non-diabetic individuals. Diabetes Care 2010, 33:1297-1299.
10. Lehmann R., Spinas G.A., Moritz W., Weber M. Has time come for new goals in human islet transplantation?. Am J Transplant 2008, 8:1096-1100.
11. Vantyghem M.-C., Raverdy V., Balavoine A.-S., Defrance F., Caiazzo R., Arnalsteen L., et al. Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3). J Clin Endocrinol Metab 2012, 97:E2078-E2083.
12. Barton F.B., Rickels M.R., Alejandro R., Hering B.J., Wease S., Naziruddin B., et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012, 35:1436-1445.
13. Thompson D.M., Meloche M., Ao Z., Paty B., Keown P., Shapiro R.J., et al. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation 2011, 91:373-378.
14. Vantyghem M.-C., Marcelli-Tourvieille S., Fermon C., Duhamel A., Raverdy V., Arnalsteen L., et al. Intraperitoneal insulin infusion versus islet transplantation: comparative study in patients with type 1 diabetes. Transplantation 2009, 87:66-71.
15. Gerber P.A., Pavlicek V., Demartines N., Zuellig R., Pfammatter T., Wüthrich R., et al. Simultaneous islet-kidney vs. pancreas-kidney transplantation in type 1 diabetes mellitus: a 5-year single centre follow-up. Diabetologia 2008, 51:110-119.
16. Maffi P., Scavini M., Socci C., Piemonti L., Caldara R., Gremizzi C., et al. Risks and benefits of transplantation in the cure of type 1 diabetes: whole pancreas versus islet transplantation. A single center study. Rev Diabet Stud 2011, 8:44-50.
17. Pattou F., Kerr-Conte J., Wild D. GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. N Engl J Med 2010, 363:1289-1290.
18. Echeverri G.J., McGrath K., Bottino R., Hara H., Dons E.M., van der Windt D.J., et al. Endoscopic gastric submucosal transplantation of islets (ENDO-STI): technique and initial results in diabetic pigs. Am J Transplant 2009, 9:2485-2496.
19. Senior P.A., Zeman M., Paty B.W., Ryan E.A., Shapiro A.M.J. Changes in renal function after clinical islet transplantation: four-year observational study. Am J Transplant 2007, 7:91-98.
20. Warnock G.L., Thompson D.M., Meloche R.M., Shapiro R.J., Ao Z., Keown P., et al. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation. 2008, 86:1762-1766.
21. Del Carro U., Fiorina P., Amadio S., De Toni Franceschini L., Petrelli A., Menini S., et al. Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation: neurophysiological and skin biopsy longitudinal analysis. Diabetes Care 2007, 30:3063-3069.
22. Solders G., Tydén G., Persson A., Groth C.G. Improvement of nerve conduction in diabetic neuropathy. A follow-up study 4 yr after combined pancreatic and renal transplantation. Diabetes 1992, 41:946-951.
23. Venturini M., Fiorina P., Maffi P., Losio C., Vergani A., Secchi A., et al. Early increase of retinal arterial and venous blood flow velocities at color Doppler imaging in brittle type 1 diabetes after islet transplant alone. Transplantation 2006, 81:1274-1277.
24. Danielson K.K., Hatipoglu B., Kinzer K., Kaplan B., Martellotto J., Qi M., et al. Reduction in carotid intima-media thickness after pancreatic islet transplantation in patients with type 1 diabetes. Diabetes Care 2013, 36:450-456.
25. Tharavanij T., Betancourt A., Messinger S., Cure P., Leitao C.B., Baidal D.A., et al. Improved long-term health-related quality of life after islet transplantation. Transplantation 2008, 86:1161-1167.
26. Benhamou P.Y., Milliat-Guittard L., Wojtusciszyn A., Kessler L., Toso C., Baertschiger R., et al. Quality of life after islet transplantation: data from the GRAGIL 1 and 2 trials. Diabet Med 2009, 26:617-621.
27. Lacotte S., Berney T., Shapiro A.J., Toso C. Immune monitoring of pancreatic islet graft: towards a better understanding, detection and treatment of harmful events. Expert Opin Biol Ther 2011, 11:55-66.
28. Huurman V.A.L., Hilbrands R., Pinkse G.G.M., Gillard P., Duinkerken G., van de Linde P., et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 2008, 3:e2435.
29. Roelen D.L., Huurman V.A.L., Hilbrands R., Gillard P., Duinkerken G., van der Meer-Prins P.W.M., et al. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. Clin Exp Immunol 2009, 156:141-148.
30. Sutherland D.E., Goetz F.C., Sibley R.K. Recurrence of disease in pancreas transplants. Diabetes 1989, 38(Suppl. 1):85-87.
31. Rickels M.R., Liu C., Shlansky-Goldberg R.D., Soleimanpour S.A., Vivek K., Kamoun M., et al. Improvement in β-cell secretory capacity following human islet transplantation according to the CIT07 protocol. Diabetes 2013, 62:2890-2897.
32. Piemonti L., Everly M.J., Maffi P., Scavini M., Poli F., Nano R., et al. Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes 2012, 62:1656-1664.
33. Ozbay L.A., Møller N., Juhl C., Bjerre M., Carstens J., Rungby J., et al. The impact of calcineurin inhibitors on insulin sensitivity and insulin secretion: a randomized crossover trial in uraemic patients. Diabet Med 2012, 29:e440-e444.
34. Lamming D.W., Ye L., Katajisto P., Goncalves M.D., Saitoh M., Stevens D.M., et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012, 335:1638-1643.
35. Parent R., Kolippakkam D., Booth G., Beretta L. Mammalian target of rapamycin activation impairs hepatocytic differentiation and targets genes moderating lipid homeostasis and hepatocellular growth. Cancer Res 2007, 67:4337-4345.
36. Shapiro A.M.J., Suarez-Pinzon W.L., Power R., Rabinovitch A. Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice. Diabetologia 2002, 45:224-230.
37. Nishimura R., Nishioka S., Fujisawa I., Shiku H., Shimada M., Sekiguchi S., et al. Tacrolimus inhibits the revascularization of isolated pancreatic islets. PLoS ONE 2013, 8:e56799.
38. Huurman V.A.L., van der Torren C.R., Gillard P., Hilbrands R., van der Meer-Prins E.P.M.W., Duinkerken G., et al. Immune responses against islet allografts during tapering of immunosuppression - a pilot study in 5 subjects. Clin Exp Immunol 2012, 169:190-198.
39. Moberg L., Johansson H., Lukinius A., Berne C., Foss A., Källen R., et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002, 360:2039-2045.
40. Elliott R.B. Towards xenotransplantation of pig islets in the clinic. Curr Opin Organ Transplant 2011, 16:195-200.
41. Vaithilingam V., Fung C., Ratnapala S., Foster J., Vaghjiani V., Manuelpillai U., et al. Characterisation of the xenogeneic immune response to microencapsulated fetal pig islet-like cell clusters transplanted into immunocompetent C57BL/6 mice. PLoS ONE 2013, 8:e59120.
42. Ravassard P., Hazhouz Y., Pechberty S., Bricout-Neveu E., Armanet M., Czernichow P., et al. A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion. J Clin Invest 2011, 121:3589-3597.
43. Sutherland D.E.R., Radosevich D., Gruessner R., Gruessner A., Kandaswamy R. Pushing the envelope: living donor pancreas transplantation. Curr Opin Organ Transplant 2012, 17:106-115.
44. Mukai E., Toyoda K., Kimura H., Kawashima H., Fujimoto H., Ueda M., et al. GLP-1 receptor antagonist as a potential probe for pancreatic beta-cell imaging. Biochem Biophys Res Commun 2009, 389:523-526.
45. Dufrane D., Gianello P. Macro- or microencapsulation of pig islets to cure type 1 diabetes. World J Gastroenterol 2012, 18:6885-6893.
46. Park Y.J., Ao Z., Kieffer T.J., Chen H., Safikhan N., Thompson D.M., et al. The glucagon-like peptide-1 receptor agonist exenatide restores impaired pro-islet amyloid polypeptide processing in cultured human islets: implications in type 2 diabetes and islet transplantation. Diabetologia 2013, 56:508-519.
47. Ye J., Liao Y.T., Jian Y.Q., Zhang X.D., Wei P., Qi H., et al. Alpha-1-antitrypsin for the improvement of autoimmunity and allograft rejection in beta cell transplantation. Immunol Lett 2013, 150:61-68.
48. Hughes A., Mohanasundaram D., Kireta S., Jessup C.F., Drogemuller C.J., Coates P.T.H. Insulin-Like growth factor-II (IGF-II) prevents proinflammatory cytokine-induced apoptosis and significantly improves islet survival after transplantation. Transplantation 2013, 95:671-678.
49. Luo J.Z.Q., Xiong F., Al-Homsi A.S., Ricordi C., Luo L. Allogeneic bone marrow cocultured with human islets significantly improves islet survival and function in vivo. Transplantation 2013, 95:801-809.
50. Hering B.J., Kandaswamy R., Ansite J.D., Eckman P.M., Nakano M., Sawada T., et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005, 293:830-835.
51. Badet L., Benhamou P.Y., Wojtusciszyn A., Baertschiger R., Milliat-Guittard L., Kessler L., et al. Expectations and strategies regarding islet transplantation: metabolic data from the GRAGIL 2 trial. Transplantation 2007, 84:89-96.
52. Froud T., Ricordi C., Baidal D.A., Hafiz M.M., Ponte G., Cure P., et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005, 5:2037-2046.
53. Gangemi A., Salehi P., Hatipoglu B., Martellotto J., Barbaro B., Kuechle J.B., et al. Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant 2008, 8:1250-1261.
54. Bellin M.D., Kandaswamy R., Parkey J., Zhang H.-J., Liu B., Ihm S.H., et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant 2008, 8:2463-2470.
55. O'Connell P.J., Holmes-Walker D.J., Goodman D., Hawthorne W.J., Loudovaris T., Gunton J.E., et al. Multicenter Australian trial of islet transplantation: improving accessibility and outcomes. Am J Transplant 2013, 3:1850-1858.
56. Turgeon N.A., Avila J.G., Cano J.A., Hutchinson J.J., Badell I.R., Page A.J., et al. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant 2010, 10:2082-2091.
57. Takita M., Matsumoto S., Shimoda M., Chujo D., Itoh T., Sorelle J.A., et al. Safety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation. Clin Transplant 2012, 26:E471-E484.
58. Lehmann R., Weber M., Berthold P., Züllig R., Pfammatter T., Moritz W., et al. Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up. Am J Transplant 2004, 4:1117-1123.
59. Toso C., Baertschiger R., Morel P., Bosco D., Armanet M., Wojtusciszyn A., et al. Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. Am J Transplant 2006, 6(5 Pt 1):1049-1058.
60. Cure P., Pileggi A., Froud T., Messinger S., Faradji R.N., Baidal D.A., et al. Improved metabolic control and quality of life in seven patients with type 1 diabetes following islet after kidney transplantation. Transplantation 2008, 85:801-812.
61. Niclauss N., Wojtusciszyn A., Brault C., Demuylder-Mischler S., Müller Y., Giovannoni L., et al. Impact of the number of infusions on 2-year results of islet-after-kidney transplantation in the GRAGIL network. Transplantation 2011, 92:1031-1038.